Identification and graduation of chemotherapy adverse events in elderly patients and comparison with predictive model of toxicities

• Grant number: 15/18737-5
• Support Opportunities: Scholarships in Brazil - Scientific Initiation
• Effective date (Start): December 01, 2015
• Effective date (End): November 30, 2017
• Field of knowledge: Health Sciences - Medicine - Medical Clinics
• Principal Investigator: Fernanda Maris Peria
• Grantee: João Vitor Barbosa de Resende
• Host Institution: Faculdade de Medicina de Ribeirão Preto (FMRP). Universidade de São Paulo (USP). Ribeirão Preto , SP, Brazil

Abstract

Secondary chemotherapy adverse events are more frequent in elderly patients, due to functional decline of various organs, like liver, kidneys and pharmacodynamics changes consequent to water body reduction, comorbidities and concomitant medications for chronic diseases. Usually elderly patients with cancer are undertreated, despite several studies showing that these patients could have the same benefits of chemotherapy compared with younger adults' patients. There are no consensuses of what specific criteria could predict which elderly patients have a higher risk of developing toxicity after standard chemotherapy dose. The objectives of this study are to identify the toxicities secondary to chemotherapy in elderly patients, graduate them according to CTCAE (Common Terminology Criteria for Adverse Events), and compare the toxicities identified with predictive toxicity model proposed by Hurria. It will be invited only patients aged greater than 60 years with all cancer diagnosis and those in second or some more cycles of chemotherapy, followed in Oncology Clinical Hospital of the Faculty of Medicine of Ribeirão Preto, University of São Paulo (USP-HCFMRP). After reading, agreement and signing the Informed Consent Form (ICF), they will be interviewed according to a structured questionnaire and all the adverse events described by patients considering the last cycle of chemo, will be graduated. All this contact with patients will be during the period of time that they will receive the infusion of chemotherapy. The results will be submitted to a statistical analysis, comparing the scores found by the predictive model described by Hurria and the percentage of grades 2-4 adverse events through correlation analyzes.